tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Harrison, 559 are a BUY (61.43%), 273 are a HOLD (30%), 78 are a SELL (8.57%).
Analyst Matthew Harrison, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 67.42% that have a potential upside of 31.44% achieved within 255 days.
Matthew Harrison’s has documented 1,777 price targets and ratings displayed on 92 stocks. The coverage is on Healthcare, Technology, Basic Materials, Energy sectors.
Most recent stock forecast was given on BIIB, Biogen at 12-Dec-2025.
Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%) receiving and performance score of 121.08.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 26-Apr-2021
$7
$3.34 (91.26%)
2 months 26 days ago
(16-Oct-2025)
1/12 (8.33%)
$2.87 (69.49%)
70
Buy
Since 28-Mar-2024
$10
$6.34 (173.22%)
$10
4 months 29 days ago
(13-Aug-2025)
0/4 (0%)
$6.91 (223.62%)
Buy
Since 10-May-2022
$5
$1.34 (36.61%)
$8
6 months 22 days ago
(20-Jun-2025)
0/9 (0%)
$2.23 (80.51%)
Sell
Since 24-Apr-2023
$1
$-2.66 (-72.68%)
$2
2 years 2 months 25 days ago
(17-Oct-2023)
2/4 (50%)
$0.23 (29.87%)
30
Hold
Since 10-Aug-2023
$5
2 years 5 months 1 days ago
(10-Aug-2023)
1/2 (50%)
$-0.07 (-1.38%)
2
Which stock is Matthew Harrison is most bullish on?
Which stock is Matthew Harrison is most reserved on?
What Year was the first public recommendation made by Matthew Harrison?
